Jane Robertson, MD

The Christie Hospital and Manchester Cancer Research Centre, Division of Cancer Sciences, United Kingdom

Poster(s):

• 1506 - Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from an ongoing Phase 1a study